NCT03336398View on ClinicalTrials.gov

Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

June 17, 2023

Study Completion Date

July 1, 2024

Conditions
Tinnitus
Interventions
DRUG

Ketamine Hydrochloride in saline

0.5 mg/kg IV of ketamine hydrochloride in saline will be administered with one of the MRS Scan

DRUG

Saline

Saline will be administered with the other MRS scan

Trial Locations (1)

10032

1051 Riverside Drive, New York

All Listed Sponsors
lead

New York State Psychiatric Institute

OTHER

NCT03336398 - Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus | Biotech Hunter | Biotech Hunter